<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    SINTX Technologies

    SINTX Technologies

    SINTX Technologies is an OEM ceramics company that develops and commercializes sil...

    SINTX Technologies is an OEM ceramics company t...

    Amount Raised:    $162,700,000
    Filing Type:    PU
    Pacira BioSciences, Inc.

    Pacira BioSciences, Inc.

    Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the deve...

    Pacira BioSciences, Inc. is a specialty pharmac...

    Filing Type:    PU
    VBI Vaccines, Inc.

    VBI Vaccines, Inc.

    VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company d...

    VBI Vaccines Inc. (Nasdaq: VBIV) is a commercia...

    Filing Type:    PU
    Sonova Holding AG

    Sonova Holding AG

    Sonova, headquartered in Stäfa, Switzerland, is a leading provider of innovative h...

    Sonova, headquartered in Stäfa, Switzerland, is...

    Filing Type:    PU
    Mirati Therapeutics, Inc.

    Mirati Therapeutics, Inc.

    Mirati Therapeutics (NASDAQ: MRTX) is a San Diego-based clinical-stage biotechnolo...

    Mirati Therapeutics (NASDAQ: MRTX) is a San Die...

    Filing Type:    PU
    Krystal Biotech, Inc.

    Krystal Biotech, Inc.

    We are a gene therapy company dedicated to developing and commercializing novel tr...

    We are a gene therapy company dedicated to deve...

    Filing Type:    PU
    Neoleukin Therapeutics, Inc.

    Neoleukin Therapeutics, Inc.

    Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...

    Neoleukin is a biopharmaceutical company creati...

    Filing Type:    PU
    Merus N.V.

    Merus N.V.

    Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...

    Merus is a clinical-stage immuno-oncology compa...

    Filing Type:    PU
    Cellectis S.A.

    Cellectis S.A.

    Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...

    Cellectis is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Moleculin Biotech, Inc.

    Moleculin Biotech, Inc.

    Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the ...

    Moleculin Biotech, Inc. is a clinical stage pha...

    Filing Type:    PU
    20/20 GeneSystems, Inc.

    20/20 GeneSystems, Inc.

    20/20 GeneSystems, Inc. an early stage digital diagnostics company with the core m...

    20/20 GeneSystems, Inc. an early stage digital ...

    Fundraising Status:    SASBEC
    Filing Type:    RA
    argenx SE

    argenx SE

    argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...

    argenx is a clinical-stage biotechnology compan...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.